| 1 |
30668408 | Demethoxycurcumin sensitizes the response of non-small cell lung cancer to cisplatin through downregulation of TP and ERCC1-related pathways. | 2019 Feb |
1 |
| 2 |
21224584 | [ERCC1 and TS expression in chemoradiotherapy treated esophageal squamous cell carcinoma]. | 2010 Nov |
2 |
| 3 |
19381033 | [Histoculture drug response assay guided adjuvant chemotherapy in patients with ERCC1-positive non-small cell lung cancer]. | 2009 Apr |
4 |
| 4 |
21475919 | Excision-repair cross-complementing 1 predicts response to cisplatin-based neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma. | 2009 Nov-Dec |
5 |
| 5 |
18751380 | Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer. | 2008 Jul-Aug |
1 |
| 6 |
17353624 | [DNA repair as a determinant of tumour chemosensitivity]. | 2007 Mar |
1 |
| 7 |
15720263 | Chemoresistance in non-small cell lung cancer. | 2005 Jan |
1 |
| 8 |
10741696 | Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. | 2000 Mar |
1 |